NASDAQ : GILD
Gilead Sciences, Inc. — Key statistics
Healthcare · Drug Manufacturers - General · United States
Last price 165.61 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 205.35B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 211.27B |
| Enterprise Value | 229.55B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Dec 15, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.24B |
| Shares Outstanding | 1.24B |
| Shares Change (YoY) | -1.59% |
| Shares Change (QoQ) | +0.64% |
| Owned by Insiders (%) | 0.09% |
| Owned by Institutions (%) | 90.79% |
| Float | 1.24B |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 20.77 |
| PS Ratio | 6.82 |
| Forward PS | 6.47 |
| PB Ratio | 16.21 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.33 |
| P/OCF Ratio | 14.59 |
| PEG Ratio | 2.85 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 7.41 |
| EV / EBITDA | 15.66 |
| EV / EBIT | 19.38 |
| EV / FCF | 16.66 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.38 |
| Quick Ratio | 1.08 |
| Debt / Equity | 2.02 |
| Debt / EBITDA | 1.77 |
| Debt / FCF | 1.90 |
| Interest Coverage | 11.72 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -22.45% |
| Return on Assets (ROA) | 13.47% |
| Return on Invested Capital (ROIC) | 36.82% |
| Return on Capital Employed (ROCE) | 30.06% |
| Weighted Average Cost of Capital (WACC) | 5.74% |
| Revenue Per Employee | $1.82M |
| Profits Per Employee | -$227,176 |
| Employee Count | 17,000 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 3.38 |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.33B |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.33 |
| 52-Week Price Change | +42.19% |
| 50-Day Moving Average | 151.36 |
| 200-Day Moving Average | 140.13 |
| Relative Strength Index (RSI) | 73.50 |
| Average Volume (20 Days) | 6,406,689 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 20.27M |
| Short Previous Month | 21.83M |
| Short % of Shares Out | 1.63% |
| Short % of Float | 1.64% |
| Short Ratio (days to cover) | 3.40 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 30.99B |
| Gross Profit | 24.77B |
| Operating Income | 11.85B |
| Pretax Income | -2.53B |
| Net Income | -3.86B |
| EBITDA | 14.66B |
| EBIT | 11.85B |
| Loss Per Share | -$3.12 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 7.95B |
| Total Debt | 26.23B |
| Net Cash | -18.28B |
| Net Cash Per Share | -$14.74 |
| Equity (Book Value) | 12.96B |
| Book Value Per Share | 10.51 |
| Working Capital | 4.55B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 14.48B |
| Capital Expenditures | -699.00M |
| Depreciation & Amortization | 2.81B |
| Net Borrowing | 1.28B |
| Free Cash Flow | 13.78B |
| FCF Per Share | $11.11 |
Margins
| Measure | Value |
|---|
| Gross Margin | 79.95% |
| Operating Margin | 38.23% |
| Pretax Margin | -8.17% |
| Profit Margin | -12.46% |
| EBITDA Margin | 47.31% |
| EBIT Margin | 38.23% |
| FCF Margin | 44.47% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $3.28 |
| Dividend Yield | 1.93% |
| Dividend Growth (YoY) | 3.80% |
| Years of Dividend Growth | 10 |
| Payout Ratio | n/a |
| FCF Payout Ratio | 29.52% |
| Buyback Yield | 1.59% |
| Shareholder Yield | 3.51% |
| Earnings Yield | -1.83% |
| FCF Yield | 6.52% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $172.50 |
| Price Target Difference | 1.27% |
| Analyst Consensus | Buy |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | 5.85% |
| EPS Growth Forecast (3Y) | 10.21% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 28, 2013 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 4.14 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |